Abstract
Erectile dysfunction (ED) is a highly prevalent condition with a variety of possible risk factors and/or etiologies. Despite significant advances regarding ED pharmacological management, there are still insufficient responders to existing pharmacological treatments e.g., approximately 30% of patients are insufficient responders to phosphodiesterase type 5 inhibitors (PDE5-Is). It has been recently proposed that botulinum toxin A intracavernosally (IC) delivered could be effective in these patients. Data from a retrospective uncontrolled single center study of 47 ED patients, consecutively recruited, insufficient responders to existing pharmacological treatments e.g., PDE5-Is or IC PGE1 injections treated with IC abobotulinumtoxinA 250 or 500 U as free combination with their existing treatment have been analyzed. Response rate, according to the International Index of Erectile Function-Erectile Function domain score, 6 weeks following IC abobotulinumtoxinA in combination with prior pharmacological treatment, was 54%. Two patients have reported mild penile pain on injection or during the 3 days following injection. Therapeutic efficacy did not seem to be influenced by the etiologies and/or risk factors for ED. Conversely, the less severe ED, the higher the response rate. Preliminary evidence for the therapeutical potential with acceptable safety of IC abobotulinumtoxinA as add-on therapy for ED not sufficiently responsive to standard therapy should be confirmed in randomized clinical trials.
Highlights
Erectile dysfunction (ED) is not a disease but a symptom
In order to further investigate the safety and efficacy of botulinum toxin A (BTX-A) for the treatment of ED, we report retrospective data from an open label study of intracavernosal abobotulinumtoxinA (Dysport® ) as add on therapy to phosphodiesterase type 5 inhibitors (PDE5-Is) or PGE1 ICI for the treatment of adult men with ED to improve erectile function when this has not been provided by PDE5-Is or PGE1 ICI alone
The total is superior to 100% because for some patients there was more than one risk factor and/or etiology for ED
Summary
Erectile dysfunction (ED) is not a disease but a symptom. ED is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance [1]. Penile erection is a complex phenomenon which implies a delicate and co-ordinated equilibrium among the neurological, vascular and the tissue compartments. It includes arterial dilation, trabecular smooth muscle relaxation, and activation of the corporeal veno-occlusive mechanism [2]. ED prevalence varies from one region of the globe to another. The age of 40, prevalence of ED is 1–10%. The prevalence ranges from 2% to 9%, as high as 15%. The 50–59 years of age group shows the greatest range of reported prevalence rates. Most of the world showed a rather high rate of 20–40% for the ages
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
